An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis
暂无分享,去创建一个
Matthew Franklin | James Lomas | Simon Walker | Tracey Young | S. Walker | M. Franklin | James Lomas | T. Young | S. Walker
[1] Roland R. Ramsahai,et al. From sample average treatment effect to population average treatment effect on the treated: combining experimental with observational studies to estimate population treatment effects , 2015 .
[2] K. Claxton,et al. Discounting in Economic Evaluations , 2018, PharmacoEconomics.
[3] F. Hamdy,et al. Validation of the Hospital Episode Statistics Outpatient Dataset in England , 2016, PharmacoEconomics.
[4] J. Edmans,et al. Cost-Effectiveness of a Specialist Geriatric Medical Intervention for Frail Older People Discharged from Acute Medical Units: Economic Evaluation in a Two-Centre Randomised Controlled Trial (AMIGOS) , 2015, PloS one.
[5] Karl Claxton,et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.
[6] A Briggs,et al. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.
[7] A. Lloyd. Special Edition on Utility Measurement, PharmacoEconomics , 2017, PharmacoEconomics.
[8] P. van Baal,et al. Future Costs in Cost-Effectiveness Analyses: Past, Present, Future , 2018, PharmacoEconomics.
[9] G. Tinghög. Legitimate basis for discounting 1 Discounting , Preferences , and Paternalism in Cost-Effectiveness Analysis , 2012 .
[10] Andrew M. Jones,et al. A quasi‐Monte‐Carlo comparison of parametric and semiparametric regression methods for heavy‐tailed and non‐normal data: an application to healthcare costs , 2015, Journal of the Royal Statistical Society. Series A,.
[11] Patrick Hamilton,et al. The economic burden of cancer in the UK: a study of survivors treated with curative intent , 2016, Psycho-oncology.
[12] Salah Ghabri,et al. Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution? , 2018, PharmacoEconomics.
[13] Corine S. Meppelink,et al. Validation of the short assessment of health literacy (SAHL-D) and short-form development: Rasch analysis , 2019, BMC Medical Research Methodology.
[14] K. van der Hoek,et al. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. , 2012, Lung cancer.
[15] K. Land,et al. An Empirical Evaluation of the Predictive Mean Matching Method for Imputing Missing Values , 1997 .
[16] G. Tomlinson,et al. Techniques for estimating health care costs with censored data: an overview for the health services researcher , 2012, ClinicoEconomics and outcomes research : CEOR.
[17] D. Owens,et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] M. Sculpher,et al. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.
[19] J. Gladman,et al. Economic Evaluation of a General Hospital Unit for Older People with Delirium and Dementia (TEAM Randomised Controlled Trial) , 2011, Trials.
[20] John Brazier,et al. The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment , 2017, PharmacoEconomics.
[21] J. Brazier,et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.
[22] Andrew Briggs,et al. Transportability of comparative effectiveness and cost-effectiveness between countries. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] Andrew Briggs,et al. Missing... presumed at random: cost-analysis of incomplete data. , 2003, Health economics.
[24] S. Walker,et al. Appropriate perspectives for health care decisions. , 2010 .
[25] R. M. Harvey,et al. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels , 1973 .
[26] M. Rutten-van Mölken,et al. The Road Not Taken: Transferability Issues in Multinational Trials , 2013, PharmacoEconomics.
[27] B. Efron. Nonparametric estimates of standard error: The jackknife, the bootstrap and other methods , 1981 .
[28] Jan Kottner,et al. The exchangeability of self-reports and administrative health care resource use measurements: assessement of the methodological reporting quality. , 2016, Journal of clinical epidemiology.
[29] M C Hornbrook,et al. Modeling risk using generalized linear models. , 1999, Journal of health economics.
[30] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[31] Paul J Rathouz,et al. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.
[32] S. Walker,et al. Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care , 2018, PloS one.
[33] Mark Sculpher,et al. Subgroups and Heterogeneity in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[34] Andrew M. Jones. Models for Health Care , 2010 .
[35] Peter Tyrer,et al. Comparison of alternative methods of collection of service use data for the economic evaluation of health care interventions. , 2007, Health economics.
[36] Uwe Siebert,et al. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[37] Andrea Manca,et al. NICE DSU TECHNICAL SUPPORT DOCUMENT 17: THE USE OF OBSERVATIONAL DATA TO INFORM ESTIMATES OF TREATMENT EFFECTIVENESS IN TECHNOLOGY APPRAISAL: METHODS FOR COMPARATIVE INDIVIDUAL PATIENT DATA , 2015 .
[38] Dyfrig A Hughes,et al. Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] James Lomas,et al. Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution. , 2015, Health economics.
[40] Tracey A. Young,et al. Estimating mean total costs in the presence of censoring , 2012, PharmacoEconomics.
[41] S. Walker,et al. Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER) , 2016, European heart journal. Quality of care & clinical outcomes.
[42] I. White,et al. Review of inverse probability weighting for dealing with missing data , 2013, Statistical methods in medical research.
[43] M. Drummond,et al. Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .
[44] M Sculpher,et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.
[45] Andrew R Willan,et al. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.
[46] Dyfrig A Hughes,et al. Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[47] Daniel Polsky,et al. Economic Evaluation in Clinical Trials , 2007 .
[48] J. Lewsey,et al. Spoilt for choice: implications of using alternative methods of costing hospital episode statistics. , 2012, Health economics.
[49] Nigel Rice,et al. HEALTH ECONOMETRICS , 2018 .
[50] C. Dirksen,et al. How to Deal with Cost Differences at Baseline , 2012, PharmacoEconomics.
[51] Karl Claxton,et al. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.
[52] M. Davies,et al. Hospital episode statistics: improving the quality and value of hospital data: a national internet e-survey of hospital consultants , 2012, BMJ Open.
[53] Miquel Porta,et al. A Dictionary of Epidemiology , 2008 .
[54] Mirjam Kretzschmar,et al. Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5 , 2012, Value in Health.
[55] A. Vassall,et al. Cost-Effectiveness Thresholds in Global Health: Taking a Multisectoral Perspective. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[56] D. Rubin,et al. Statistical Analysis with Missing Data , 1988 .
[57] Karl Claxton,et al. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[58] J. Brazier,et al. A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models , 2017, PharmacoEconomics.
[59] J. Heckman. The Common Structure of Statistical Models of Truncation, Sample Selection and Limited Dependent Variables and a Simple Estimator for Such Models , 1976 .
[60] A. Akobeng. Understanding randomised controlled trials , 2005, Archives of Disease in Childhood.
[61] Patrick Royston,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[62] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[63] S. Thompson,et al. Multiple regression of cost data: use of generalised linear models , 2004, Journal of health services research & policy.
[64] James R Carpenter,et al. Missing data in trial‐based cost‐effectiveness analysis: An incomplete journey , 2018, Health economics.
[65] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[66] M. Franklin,et al. Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study , 2017, PharmacoEconomics.
[67] Andrew R Willan,et al. Regression methods for cost‐effectiveness analysis with censored data , 2005, Statistics in medicine.
[68] D. Rowen,et al. International Regulations and Recommendations for Utility Data for Health Technology Assessment , 2017, PharmacoEconomics.
[69] Karl Claxton,et al. Discounting and decision making in the economic evaluation of health-care technologies. , 2011, Health economics.
[70] Spiros C. Denaxas,et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study , 2013, BMJ.
[71] Jonathan Karnon,et al. Modeling Using Discrete Event Simulation , 2012 .
[72] Richard Grieve,et al. Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[73] M Sculpher,et al. EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. , 2012, Health technology assessment.
[74] Cost, context and decisions in Health Economics and cost-effectiveness analysis , 2018 .
[75] T. Roberts,et al. Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies , 2015, PloS one.
[76] B. Winblad,et al. Application of Resource Utilization in Dementia (RUD) instrument in a global setting , 2013, Alzheimer's & Dementia.
[77] Mark J Sculpher,et al. Dangerous omissions: the consequences of ignoring decision uncertainty. , 2011, Health economics.
[78] R. Deyo,et al. Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life , 1989, Medical care.
[79] Core items for a standardized resource-use measure (ISRUM) , 2017 .
[80] Matthew Franklin,et al. Self-reported and routinely collected electronic healthcare resource-use data for trial-based economic evaluations: the current state of play in England and considerations for the future , 2019, BMC Medical Research Methodology.
[81] Martin Knapp,et al. Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation , 2013, Applied Health Economics and Health Policy.
[82] Anthony O'Hagan,et al. Review of Statistical Methods for Analysing Healthcare Resources and Costs , 2010, Health economics.
[83] Mark Sculpher,et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[84] Jonathan Karnon,et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[85] Nicholas R Latimer,et al. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[86] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[87] Andrea Manca,et al. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. , 2004, Health economics.
[88] Identifying patient-level health and social care costs for older adults discharged from acute medical units in England. , 2014, Age and ageing.
[89] M. Yeh,et al. A real world cost effectiveness analysis of interferon‐based therapy for HCV naïve super‐responders , 2018, Journal of the Chinese Medical Association : JCMA.
[90] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[91] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[92] Martin Knapp,et al. Costing psychiatric interventions. , 1992 .
[93] J. Lewis,et al. Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. , 1999, Statistics in medicine.
[94] Sylvie Chevret,et al. A multiple imputation approach for MNAR mechanisms compatible with Heckman's model , 2016, Statistics in medicine.
[95] R. Goeree,et al. The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions , 2012, PharmacoEconomics.
[96] W. Manning,et al. Estimating Log Models: To Transform or Not to Transform? , 1999, Journal of health economics.
[97] N. Freemantle,et al. An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis , 2015, PharmacoEconomics.
[98] M. Drummond,et al. Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.
[99] P. Deb,et al. Modeling Health Care Expenditures and Use. , 2018, Annual review of public health.
[100] John Van Hoewyk,et al. A multivariate technique for multiply imputing missing values using a sequence of regression models , 2001 .
[101] S. Willich,et al. Economic analysis based on multinational studies: methods for adapting findings to national contexts , 2010, Journal of Public Health.
[102] A. Basu,et al. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. , 2005, Biostatistics.
[103] A H Briggs,et al. Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.
[104] M. Deidda,et al. A framework for conducting economic evaluations alongside natural experiments , 2019, Social science & medicine.
[105] P. Deb,et al. Modeling Health Care Costs and Counts , 2010 .
[106] K Claxton,et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. , 2012, Health technology assessment.
[107] D. Kendrick,et al. Identification of incident poisoning, fracture and burn events using linked primary care, secondary care and mortality data from England: implications for research and surveillance , 2015, Injury Prevention.
[108] A. Monfort,et al. Fourth Order Pseudo Maximum Likelihood Methods , 2008 .
[109] L. Seymour,et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. , 2010, Journal of the National Cancer Institute.
[110] E. Faerstein,et al. A DICTIONARY OF EPIDEMIOLOGY , 2016 .
[111] Peisong Han,et al. Combining Inverse Probability Weighting and Multiple Imputation to Improve Robustness of Estimation , 2016 .
[112] Alec Morton,et al. Health care input constraints and cost effectiveness analysis decision rules , 2018, Social science & medicine.
[113] S. Walker,et al. Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities , 2016, PharmacoEconomics.
[114] M Sculpher,et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.